Androjen antagonistleri.Abirateron asetat (han, ABD, YASAK, OCA) (marka isimleri Zytiga, Abirate, Abreton, Abirapro) steroidal bir antiandrojendir, özellikle bir androjen sentezi inhibitörü, metastatik kastrasyona dirençli prostat kanserinde ile birlikte kullanılır (daha önce hormona dirençli veya hormona dirençli prostat kanseri olarak adlandırılıyordu) - yani., Androjen yoksunluğuna veya androjen reseptör antagonistleriyle tedaviye yanıt vermeyen prostat kanseri. Aktif madde abirateronun ön ilacıdır, and is marketed by Janssen Biotech under the trade name Zytiga. Ek olarak, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.
Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.
Use in Cancer Abiraterone acetate is approved to be used with to treat Prostate cancer that has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with other hormone therapy.
Abirateron ayrıca diğer kanser türlerinin tedavisinde de araştırılmaktadır..
